HAMLET B — Hamlet BioPharma AB Income Statement
0.000.00%
Last trade - 00:00- SEK1.14bn
- SEK1.13bn
Annual income statement for Hamlet BioPharma AB, fiscal year end - June 30th, SEK millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | 2026 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | SAS | SAS | SAS | SAS | SAS |
| Status: | Final | Final | Final | Final | Preliminary |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 17.1 | 20.5 | 42.5 | 55.1 | 55.8 |
| Operating Profit | -17.1 | -20.5 | -42.5 | -55.1 | -55.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -17.2 | -20.4 | -41.8 | -54.7 | -55.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -17.2 | -20.4 | -41.8 | -54.7 | -55.6 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -17.2 | -20.4 | -41.8 | -54.7 | -55.6 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -17.2 | -20.4 | -41.8 | -54.7 | -55.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.15 | -0.176 | -0.249 | -0.308 | -0.298 |
| Dividends per Share |